Feasibility and Early Outcomes of Reduced‑Intensity Allogeneic Transplantation for Myelofibrosis in a Taiwanese Center (ICBMT 2026) - Oct 8, 2026 - Abstract #PP08‑07; "All patients received uniform RIC with fludarabine, busulfan, and cyclophosphamide (Flu/Bu/Cy). GVHD prophylaxis was calcineurin inhibitor–based (cyclosporine + mycophenolate), with anti‑thymocyte globulin added in unrelated and haploidentical settings...All patients had received ruxolitinib pre‑transplant... In this single‑center series, a uniform RIC Flu/Bu/Cy platform supported reliable engraftment and was applicable across matched unrelated, matched related, and haploidentical donors, with no graft failure and no non‑relapse mortality at a median follow‑up of more than two years. GVHD and infectious complications were manageable. These early outcomes support the feasibility of a standardized RIC approach to allo‑HSCT for MF in our setting; larger cohorts and longer follow‑up are needed to confirm durability of disease control, particularly in higher‑risk and alternative‑donor transplants."
Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Diffuse Large B Cell Lymphoma • Fibrosis • Graft versus Host Disease • Immunology • Infectious Disease • Myelofibrosis • Respiratory Diseases • Septic Shock • Transplantation • Tuberculosis • JAK2
|
|
Fang‑Yu Wang 1; Wei‑Han Huang 1, 2; Min‑Feng Shih 1; Chi‑Cheng Li 1, 2
|